Rash from newer cancer agents: Why do we still not have effective therapy for palliation and/or prevention?

Matthew Butts, Aminah Jatoi

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

In their paper, "Dermatologic Toxicities of Targeted Anticancer Therapies," Balagula and others provide a thorough discussion of cutaneous adverse events from newer, targeted anticancer agents. These agents include epidermal growth factor receptor (EGFR) inhibitors, as well as several other multikinase inhibitors. The authors describe the spectrum of skin, hair, and nail changes that arise from several such agents and comprehensively expound upon the psychosocial and physical discomfort of such toxicities.

Original languageEnglish (US)
Pages (from-to)162-163
Number of pages2
JournalJournal of Supportive Oncology
Volume8
Issue number4
StatePublished - Jul 1 2010

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Rash from newer cancer agents: Why do we still not have effective therapy for palliation and/or prevention?'. Together they form a unique fingerprint.

  • Cite this